The main role of the Thai FDA is to protect consumers’ health, especially, to ensure safety, quality and efficacy of health products within its remit. These include: foods, drugs, psychotropic substances, narcotics, medical devices, volatile substances, cosmetics and hazardous substances available in the country. This has to be implemented in accordance with national legislation and international agreements as follows:
By law, certain important issues are decided by committees, whose members, all experts in their fields, are appointed by the Minister of Public Health. Currently, there are six committees : Drugs, Food, Cosmetics, Narcotics, Psychotropic Substances and Medical Devices.
There are two committees whose members are appointed by the other ministries. They are the Committee on the Prevention of Abuse of Volatile Substances appointed by two ministers (Industry and Public Health), and the Hazardous Substance Committee appointed by three ministers (Public Health, Industry and Agriculture).
At the national level, the Cabinet appoints three committees: the National Drug Committee, the National Food Committee and the National Chemical Safety Committee. The national committees are mainly assigned policy and development issues and collaborative action with other agencies to facilitate the implementation of the food, drug and chemical safety program as well as the control system.
Contact details
Address:
No. 88/24 , Tiwanon Road , Muang, Nonthaburi , 11000 , 11000
Tel: +66 02 590 7000
The biggest pharma stories from Southeast Asia, including GSK’s new HPF manufacturing investment, license suspensions for Samco Farma and Ciubros Farma after Indonesia’s acute kidney injury crisis, Kalbe’s Aventis share…
Through compassionate use programs patients suffering from critical, life-threatening conditions can access potential life-saving therapeutic options which have not been formally approved by the responsible health authority in an ethical…
Takeda’s Soon Yee Chow and Helene Sou, writing in the September 2022 edition of DIA’s Global Forum magazine, outline how digitalisation initiatives, if properly enacted, can help the ASEAN region…
Writing in the September edition of DIA’s Global Forum magazine, Rosilawati Ahmad of Malaysia’s National Pharmaceutical Regulatory Agency; Tharnkamol Chanprapaph of the Thai FDA; and Samvel Azatyan, Valerio Reggi, and…
The latest from the pharma industry in Southeast Asia, including underwhelming results from Kalbe Pharma, Indonesia’s largest pharma company; Novavax’s vaccine manufacturing plans in the Philippines; the promising future of…
PharmaBoardroom’s latest report: Healthcare & Life Sciences Review: Thailand is available for download now. Thailand is in the midst of an economic transformation with healthcare at its heart. With four years…
Shinsuke Yuasa, president of Thai Otsuka discusses the importance of Thailand for Otsuka as its first overseas market back in 1973. Yuasa goes on to highlight how the affiliate is…
Thailand country managers from three of the world’s largest medtech firms outline the level of innovation they are able to bring to the Thai market, how their technology is helping…
Nico Form-Zuellig, general manager of Interthai Pharmaceutical Manufacturing, shares his thoughts on the Thai pharmaceutical market as a newcomer to the country and goes on to elaborate on the company’s…
Philippe Pedeboscq, managing director of Siemens Healthineers, shares his impressions after taking the lead of the company’s Thailand affiliate two years ago. Pedeboscq goes on to explain his strategic mission…
Every generation of Novo Nordisk’s insulin portfolio is currently on the Thai Market and the affiliate is one of the fastest-growing pharma multinationals in Thailand. Upon this solid foundation, Novo…
Nares Damrongchai has been the CEO of the Thailand Center of Excellence for Life Science (TCELS) since its foundation in 2004. After seven years onboard, he discusses the organization’s progress…
See our Cookie Privacy Policy Here
